25 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
Parkinson's trials may study motor symptoms, wearing-off, dyskinesia, cognition, or investigational disease-modifying drugs. Hoehn and Yahr stage, levodopa dose, and device history (DBS) often decide eligibility. We do not score how well a drug works. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (12) · Phase 2 (6) · Phase 1 (2) · Phase 3 (2) · Phase 1 / Phase 2 (2) · Early phase 1 (1)
Intervention hubs that overlap this snapshot: Psilocybin · Adalimumab
Objective: This protocol is designed to allow the Surgical Neurology Branch to evaluate and treat the neurosurgical disorders of protocol participants. The participants will receive standard-of-clinical-care evaluation and treatment.
NCT00060541 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)
Background: \- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest.
NCT01581580 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)
Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.
NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder.
NCT04396873 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
This study is being done to the determine the ability and utility of using the Neuropixels probes in the human brain. A Neuropixels probe will be inserted into and removed from the brain of awake human patients who are undergoing awake Deep Brain Stimulation (DBS) surgery.
NCT06778135 · Official ClinicalTrials.gov record · University of Colorado, Denver
Study BRT-DA01-301 is a Phase 3 multicenter, randomly assigned, sham surgery-controlled, neither you nor the study doctors know who gets the real treatment study to assess how well it works and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
NCT06944522 · Official ClinicalTrials.gov record · BlueRock Therapeutics
This is a phase 2 study to assess the ability of adalimumab as compared to dummy treatment (placebo) to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.
NCT06996652 · Official ClinicalTrials.gov record · Yale University
This study wants to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-dummy treatment (placebo).
NCT07002034 · Official ClinicalTrials.gov record · Reunion Neuroscience Inc
The goal of this clinical trial is to investigate motor responses in healthy subjects and patients with movement disorders, brain and spinal cord injury, neuromuscular diseases, or cardiovascular diseases. This study aims to measure the effectiveness of traditional physical activities combined with innovative interventions such as cryotherapy, ultrasound therapy, laser therapy, transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS).
NCT07066137 · Official ClinicalTrials.gov record · IRCCS Centro Neurolesi Bonino Pulejo
In Parkinson's disease (PD), there is inflammation in the brain, the gut and the blood, which is thought to contribute to the development and progression of the disease. The Nod-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is a complex of proteins which plays a critical role in mediating inflammation, and there is growing evidence from laboratory research that the inflammasome plays a role in Parkinson's disease.
NCT07157735 · Official ClinicalTrials.gov record · Cambridge University Hospitals NHS Foundation Trust
This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.
NCT07174310 · Official ClinicalTrials.gov record · Hoffmann-La Roche
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
NCT07227896 · Official ClinicalTrials.gov record · AbbVie
This study wants to measure the dose-related whether it is safe and how hard side effects are to live with of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn \& Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available this drug alone and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary how well it works and pharmacokinetic (PK) characteristics.
NCT07371338 · Official ClinicalTrials.gov record · Innopeutics Corporation
This single-site, open-label pilot study will measure the feasibility, tolerability, and preliminary how well it works of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants with PD and clinically significant apathy will undergo imaging (EEG and MRI) and one day of TMS including twelve iTBS sessions across two visits.
NCT07399496 · Official ClinicalTrials.gov record · Medical University of South Carolina
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually.
NCT07428447 · Official ClinicalTrials.gov record · CND Life Sciences
This study wants to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
NCT07610369 · Official ClinicalTrials.gov record · Yale University
This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires.
NCT07642908 · Official ClinicalTrials.gov record · University of Michigan
This clinical study is designed to explore the whether it is safe and how hard side effects are to live with of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
NCT07733349 · Official ClinicalTrials.gov record · Shanghai UniXell Biotechnology Co., Ltd
This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of RO7568282 compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.
NCT07781644 · Official ClinicalTrials.gov record · Hoffmann-La Roche
Vista PD is a randomly assigned, compared with a dummy treatment, multicenter study to measure the how well it works, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease?
NCT07804615 · Official ClinicalTrials.gov record · Vima Therapeutics
The currently available treatments of Parkinson's disease (PD) and Essential Tremor (ET) are inadequate and accompanied by adverse side effects making the treatment much less effective. This includes treatments with pharmaceuticals as well as electrical brain stimulation (DBS; Deep Brain Stimulation).
NCT07820189 · Official ClinicalTrials.gov record · Lund University
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its whether it is safe and how hard side effects are to live with as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
NCT07863180 · Official ClinicalTrials.gov record · Prabesh Kanel
Parkinson's disease (PD) is an age-related movement disorder with a complex pathophysiology. Among the risk factors for PD, variants in beta-glucocerebrosidase (encoded by the gene GBA1) represent one of the most significant heritable risk factors for lifetime PD risk.
NCT07886879 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai
This multicenter study aims to characterize the language profiles of patients with various neurodegenerative diseases, including Alzheimer's disease (AD), Primary Progressive Aphasia (PPA), behavioral variant Frontotemporal Dementia (bvFTD), Dementia with Lewy Bodies (DLB), and Parkinson's disease (PD), using artificial intelligence (AI) models. By analyzing speech and language data collected during remote neuropsychological assessments, the researchers intend to identify objective linguistic biomarkers suitable for early and differential diagnosis, overcoming the limitations of traditional, invasive, and costly diagnostic tools.
NCT07906769 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA
This clinical study is designed to explore the whether it is safe and how hard side effects are to live with of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
NCT07911670 · Official ClinicalTrials.gov record · The First Affiliated Hospital of Anhui Medical University
This hub lists 25 recruiting Parkinson's disease studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “Parkinson disease” at https://clinicaltrials.gov/search?cond=Parkinson%20disease.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include New York, New York; Seoul, South Korea; Boston, Massachusetts; Scottsdale, Arizona; Los Angeles, California. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.
Amyloid and tau drugs, lifestyle trials, and studies for caregivers and prevention.
B-cell drugs, remyelination experiments, and progressive-MS trials.
CGRP blockers, devices, and prevention vs. rescue studies.
Drug, gene, and device studies for amyotrophic lateral sclerosis.
Add-on medicines, devices, and surgery-related studies for seizures.
Recovery, prevention after a first stroke, and acute hospital studies.